Whitaker, HC;
Ross-Adams, H;
Ball, S;
Lawrensen, K;
Halim, S;
Russell, R;
Wells, C;
... Mills, IG; + view all
(2016)
HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.
Oncotarget
10.18632/oncotarget.12543.
Preview |
Text
Main article.pdf - Accepted Version Download (2MB) | Preview |
Preview |
Text
Supplementary.pdf - Accepted Version Download (1MB) | Preview |
Preview |
Text
whitaker_supplementary tables.pdf Download (975kB) | Preview |
Abstract
Two independent regions within HNF1B are consistently identified in prostate and ovarian cancer genome-wide association studies (GWAS); their functional roles are unclear. We link prostate cancer (PC) risk SNPs rs11649743 and rs3760511 with elevated HNF1B gene expression and allele-specific epigenetic silencing, and outline a mechanism by which common risk variants could effect functional changes that increase disease risk: functional assays suggest that HNF1B is a pro-differentiation factor that suppresses epithelial-to-mesenchymal transition (EMT) in unmethylated, healthy tissues. This tumor-suppressor activity is lost when HNF1B is silenced by promoter methylation in the progression to PC. Epigenetic inactivation of HNF1B in ovarian cancer also associates with known risk SNPs, with a similar impact on EMT. This represents one of the first comprehensive studies into the pleiotropic role of a GWAS-associated transcription factor across distinct cancer types, and is the first to describe a conserved role for a multi-cancer genetic risk factor.
Archive Staff Only
View Item |